Year: 2025
Type: article
Abstract: Obesity is a significant global health challenge that increases the chance of developing cardiovascular disorders (CVDs), including heart failure, coronary artery disease, and hypertension. Traditional weight-loss methods often yield limited success, prompting the need for pharmacological interventions. Anti-obesity medications (AOMs) have emerged as effective tools for not only weight reduction but also improving cardiovascular health. This article explores the cardiovascular benefits of AOMs, including their role in lowering blood pressure, improving lipid profiles, reducing inflammation, and enhancing insulin sensitivity. Clinical trials, such as the SELECT and LEADER studies, provide strong evidence that medications like semaglutide, liraglutide, and tirzepatide significantly reduce major cardiovascular events. While AOMs offer promising heart health benefits, they should be integrated into a comprehensive lifestyle approach. This review highlights the transformative impact of anti-obesity medications in reducing cardiovascular risks and improving overall well-being.
Authors: Dr. Imran Aslam, Dr. Muhammad Kalim Raza, Dr. Ayesha Ashraf, Dr. Vishal Chauhan
Institution: Samarkand State Medical Institute
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W6893280375
FWCI:
Cites:
Cited by:
Related to: